New cancer drug combo enters first human tests
NCT ID NCT05025085
Summary
This early-stage study tested a new drug called AGEN1777, both by itself and combined with an existing immunotherapy drug, in 25 patients with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find a safe dose and understand how the body processes the drug. Researchers also looked for early signs that the treatment might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lifespan Cancer Institute
Providence, Rhode Island, 02903, United States
-
Local Institution - 0001
Providence, Rhode Island, 02903, United States
-
Local Institution - 024
Southfield, Michigan, 48075, United States
-
Local Institution - 072
Cincinnati, Ohio, 45267-0558, United States
-
Local Institution - 164
Dallas, Texas, 75230, United States
-
Local Institution - 165
Grand Rapids, Michigan, 49546, United States
-
MD Anderson Cancer Center Thoracic-Head & Neck Med Onc
Houston, Texas, 77030, United States
-
Mary Crowley Cancer Research
Dallas, Texas, 75251, United States
-
Providence Cancer Institute
Portland, Oregon, 97213, United States
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
University of Cincinnati Cancer Center
Cincinnati, Ohio, 45267, United States
Conditions
Explore the condition pages connected to this study.